CYMABAY THERAPEUTICS INC (CBAY)
US23257D1037 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 206.53M | 20.30M | 125.80M | 28.20M | 24.90M | |||
| Marketable Securities | 187.72M | 115.20M | 60.70M | 118.10M | 166.10M | |||
| Receivables | N/A | N/A | N/A | 300.00K | 700.00K | |||
| Other Current Assets | 9.55M | 2.60M | 4.60M | 5.00M | 11.30M | |||
| Total Current Assets | 403.80M | 138.10M | 191.10M | 151.60M | 202.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 5.72M | 900.00K | 1.40M | 2.00M | 2.60M | |||
| Investments And Advances | 21.93M | 0.00 | 8.10M | N/A | N/A | |||
| Other Non-Current Assets | 3.23M | 2.90M | 1.70M | 200.00K | 200.00K | |||
| Total Non-Current Assets | 30.88M | 3.80M | 11.20M | 2.20M | 2.80M | |||
| TOTAL ASSETS | 434.69M | 141.90M | 202.30M | 153.80M | 205.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 10.00M | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 21.33M | 14.30M | 15.60M | 9.60M | 15.10M | |||
| Accounts Payable | 3.83M | 1.10M | 2.70M | 200.00K | 2.50M | |||
| Other Current Liabilities | 1.69M | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 36.84M | 15.40M | 18.40M | 9.90M | 17.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 99.64M | 90.20M | 50.30M | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 5.95M | 0.00 | 700.00K | 1.30M | 1.70M | |||
| Total Non-Current Liabilities | 105.59M | 90.30M | 51.00M | 1.20M | 1.80M | |||
| TOTAL LIABILITIES | 142.43M | 105.70M | 69.40M | 11.10M | 19.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -978.23M | -872.90M | -766.90M | -676.90M | -625.90M | |||
| Additional Paid In Capital | 1.27B | 909.30M | 899.80M | 819.50M | 812.10M | |||
| Common Shares | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 144.00K | -300.00K | 0.00 | 0.00 | 100.00K | |||
| Shares Outstanding | 113.86M | 84.70M | 84.70M | 68.90M | 68.90M | |||
| Tangible Book Value per Share | 2.57 | 0.43 | 1.57 | 2.07 | 2.70 | |||
| Total Shareholders' Equity | 292.26M | 36.20M | 132.90M | 142.70M | 186.30M | |||
| TOTAL LIABILITIES AND EQUITY | 434.69M | 141.90M | 202.30M | 153.80M | 205.70M | |||
| Statistics | ||||||||
| Debt/Equity | 0.34 | 2.49 | 0.38 | N/A | N/A | |||
| Current Ratio | 10.96 | 8.97 | 10.39 | 15.31 | 11.53 | |||
| Return On Assets (ROA) | -24.24% | -74.70% | -44.49% | -33.15% | -49.98% | |||
| Return On Equity (ROE) | -36.05% | -292.82% | -67.72% | -35.73% | -55.19% | |||
All data in USD